Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...

Cassava Sciences (SAVA) stock in focus as company posts better than expected Q3 earnings and reaffirms Phase 3 timeline for ...